Fate Therapeutics is developing TCR-less T-iPSC–derived CD19-CAR-T cells where the CD19CAR is expressed from the TCR α chain constant region (TRAC) locus, while Adaptimmune aims to develop off-the-shelf anti-tumor T cells from TCR-engineered iPSC. The gene discussed is CD19; the disease is neoplasm.